Cue Biopharma, Inc.CUENASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +58.86% | -13.45% | -75.48% | +11.14% | -35.58% |
| Gross Profit Growth | +0.00% | +0.00% | -75.48% | +11.14% | -37.95% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +10.51% | +57.47% | +50.11% | +90.25% | +96.90% |
| Weighted Average Shares Diluted Growth | +10.51% | +57.47% | +50.11% | +90.25% | +96.90% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +89.77% | -44.35% | -100.00% | -71.20% | -27.47% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -34.95% | -47.68% | -58.75% | -3.83% | -29.38% |
| Book Value per Share Growth | -46.20% | -70.03% | -85.41% | -55.86% | -73.48% |
| Debt Growth | -41.92% | -39.60% | -45.18% | -32.22% | -35.10% |
| R&D Expense Growth | -4.99% | -34.01% | -16.20% | -17.00% | -50.05% |
| SG&A Expenses Growth | -36.92% | +100.15% | +25.05% | +4.67% | +71.89% |